항고지혈증제 시장 : 약물 종류별, 지역별 - 규모, 점유율, 전망, 기회 분석(2023-2030년)

Hyperlipidemia is a term that encompasses various genetic and acquired disorders that describe an elevated lipid levels, such as cholesterol and triglycerides, in the blood, which in turn increases the risk of heart disease and stroke, the leading cause of death worldwide. It is a very common disorder, and thus, there is an increasing demand for antihyperlipidemic drugs across the world, as they help reduce the risk of hyperlipidemia and cardiovascular diseases.

Market Dynamics:

Increasing prevalence of hyperlipidemia, surge in sedentary lifestyle, growing geriatric population, increasing demand for antihyperlipidemic drugs, and introduction of novel drugs are major factors expected to augment the growth of the global antihyperlipidemic drugs market.

For instance, according to the American Stroke Association, stroke is the No. 5 cause of death and a leading cause of disability in the United States. Every year, more than 795,000 people in the U.S. have a stroke. About 610,000 of these are first or new strokes.

Moreover, according to the repost by AHA Journals, in Europe, stroke is the most common cause of death as well as a leading cause of adult disability. The Stroke Action Plan for Europe (SAP-E) is a pan-European project that sets targets for the implementation of an evidence-based preventive actions and stroke services until 2030.

Key features of the study:

• This report provides in-depth analysis of the global antihyperlipidemic drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global antihyperlipidemic drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Sanofi S.A., Pfizer Inc., Mylan N.V, Amgen Inc., Abbvie Inc., Merck & Co., Inc., Dr. Reddy's Laboratories Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, and Daiichi Sankyo Company, Limited, among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global antihyperlipidemic drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antihyperlipidemic drugs market.

Detailed Segmentation:

• Global Antihyperlipidemic Drugs Market, By Drug Class:
  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others
• Global Antihyperlipidemic Drugs Market, By Geography:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles:
  • Sanofi S.A.
  • Pfizer Inc.
  • Mylan N.V.
  • Amgen Inc.
  • Abbvie Inc.
  • Merck & Co., Inc.
  • Reddy's Laboratories Ltd.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Daiichi Sankyo Company, Limited, among others.

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of hyperlipidemia worldwide
  • High cost of treatment and lack of awareness
  • Increasing demand for antihyperlipidemic drugs
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Antihyperlipidemic Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Antihyperlipidemic Drugs Market, By Drug Class, 2023-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Statins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
• Bile Acid Sequestrants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
• Cholesterol Absorption Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
• Fibric Acid Derivatives
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
• PCSK9 Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
• Combination
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)

6. Global Antihyperlipidemic Drugs Market, By Region, 2023-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)

7. Competitive Landscape

• Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Abbvie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Dr. Reddy's Laboratories Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Daiichi Sankyo Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

8. Section

• Research Methodology
• About us